Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet J C
Biochem Pharmacol. 1986 May 15;35(10):1743-51. doi: 10.1016/0006-2952(86)90333-3.
Cyclic nucleotide phosphodiesterase (PDE) activity from the 105,000 g supernatant of human, bovine and rat aorta smooth muscle cells was resolved by DEAE-trisacryl chromatography into three major forms showing similar properties in each species. In addition to the two PDE forms previously characterized in vascular tissues (a cAMP-PDE and a calmodulin-dependent PDE), a cGMP-PDE, insensitive to calmodulin, was isolated and characterized in the aorta of the three species. Each isolated PDE form was differently inhibited by various chemical compounds, and these compounds produced effects on cyclic nucleotide levels in isolated rat aorta which could be expected from their inhibitory effect on isolated PDE forms. At concentrations non-selectively inhibiting the three isolated PDE forms (including the calmodulin-dependent one), IBMX (3-isobutyl-1-methylxanthine) and trequinsin markedly and dose-dependently increased both cAMP and cGMP aorta levels (up to 7-fold, in presence of 500 microM IBMX). By contrast selective inhibitors of cGMP-PDE or cAMP-PDE could only induce a moderate elevation (by 1.5-3-fold) in cGMP or cAMP levels, respectively. In the case of M&B 22,948, a highly specific and potent inhibitor of cGMP-PDE, a concentration-dependent increase in tissue cGMP levels was produced by concentrations (in the microM range) active in inhibiting the isolated enzyme. In the case of selective cAMP-PDE inhibitors (rolipram and Ro 20-1724), however, a significant increase in aorta cAMP content was induced only in the presence of drug concentrations which were much higher (200 and 500 microM, respectively) than those inhibiting the isolated enzyme (IC50:5 and 18 microM, respectively). Inhibitors of both cGMP-PDE and cAMP-PDE (dipyridamole, cilostamide and its derivative AAL 05) produced the same moderate effects as did the combination of a selective cGMP-PDE inhibitor and a selective cAMP-PDE inhibitor on the levels of both cGMP and cAMP. These results show that the three forms of PDE isolated from aortic smooth muscle retain properties that they exhibit in the tissue and which are similar in the three species examined, including man. They suggest that each form participates in a specific manner to the regulation of cAMP and cGMP concentrations in aorta smooth muscle cells.
人、牛和大鼠主动脉平滑肌细胞105,000g上清液中的环核苷酸磷酸二酯酶(PDE)活性通过DEAE-三丙烯酸酯色谱法分离为三种主要形式,在每个物种中表现出相似的特性。除了先前在血管组织中鉴定的两种PDE形式(一种cAMP-PDE和一种钙调蛋白依赖性PDE)外,还在这三种物种的主动脉中分离并鉴定了一种对钙调蛋白不敏感的cGMP-PDE。每种分离出的PDE形式受到各种化合物的不同抑制,并且这些化合物对分离的大鼠主动脉中的环核苷酸水平产生的影响可以从它们对分离的PDE形式的抑制作用中预期得到。在非选择性抑制三种分离出的PDE形式(包括钙调蛋白依赖性形式)的浓度下,异丁基甲基黄嘌呤(IBMX)和曲喹辛显著且剂量依赖性地增加了主动脉中cAMP和cGMP的水平(在存在500μM IBMX的情况下高达7倍)。相比之下,cGMP-PDE或cAMP-PDE的选择性抑制剂只能分别使cGMP或cAMP水平适度升高(1.5至3倍)。就M&B 22,948而言,一种高度特异性和强效的cGMP-PDE抑制剂,在抑制分离酶的活性浓度(μM范围内)下,会使组织cGMP水平呈浓度依赖性增加。然而,就选择性cAMP-PDE抑制剂(咯利普兰和Ro 20-1724)而言,只有在药物浓度远高于抑制分离酶的浓度(IC50分别为5和18μM)时,才会诱导主动脉cAMP含量显著增加。cGMP-PDE和cAMP-PDE的抑制剂(双嘧达莫、西洛他唑及其衍生物AAL 05)对cGMP和cAMP水平产生的作用与选择性cGMP-PDE抑制剂和选择性cAMP-PDE抑制剂的组合相同,都是适度的作用。这些结果表明,从主动脉平滑肌中分离出的三种PDE形式保留了它们在组织中表现出的特性,并且在所研究的包括人类在内的三种物种中是相似的。它们表明每种形式以特定方式参与主动脉平滑肌细胞中cAMP和cGMP浓度的调节。